MENU

KYMR Stock Tickeron detected bullish Stock Pattern: Broadening Wedge Descending KYMR on June 02, 2025, netting in a 22.70% gain over 3 months

A.I.dvisor
at Tickeron.com
Loading...
+22.70% Gain from a Successful pattern Broadening Wedge Descending
KYMR - Kymera Therapeutics
Tickeron
Ticker: KYMR
Company: Kymera Therapeutics
Gain: +22.7%
Confirmed: 06/02/25
Succeeded: 06/02/25
Total length: 110 days
On February 12, 2025, A.I.dvisor detected a Broadening Wedge Descending Pattern (Bullish) for Kymera Therapeutics (KYMR, $35.15). On June 02, 2025, A.I.dvisor confirmed the Bullish pattern, setting a target price of $47.74. On June 02, 2025, KYMR reached the target price resulting in a +2 for traders who took a long position in the stock.

Momentum Indicator for KYMR turns positive, indicating new upward trend

KYMR saw its Momentum Indicator move above the 0 level on June 02, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for KYMR just turned positive on June 02, 2025. Looking at past instances where KYMR's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

KYMR moved above its 50-day moving average on May 29, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KYMR advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 184 cases where KYMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYMR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

KYMR broke above its upper Bollinger Band on June 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KYMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.890) is normal, around the industry mean (16.950). P/E Ratio (0.000) is within average values for comparable stocks, (59.602). KYMR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.336). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (61.728) is also within normal values, averaging (257.570).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biotechnology company, which engages in curing untreatable diseases and focuses on discovering and developing novel small molecule therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
200 Arsenal Yards Boulevard
Phone
+1 857 285-5300
Employees
187
Web
https://www.kymeratx.com